MUC16 and cervical cancer: Several lines of evidence support the potential of specific biomarkers (such as cancer antigen 125, soluble form of interleukin 2 receptor, and tumor necrosis factor for identifying early‐stage cervical cancer and providing patients with a better prognosis) [31].